Rankings
▼
Calendar
RYTM Q4 2022 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RYTM
Rhythm Pharmaceuticals, Inc.
$6B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$9M
+383.8% YoY
Gross Profit
$8M
88.3% margin
Operating Income
-$42M
-479.0% margin
Net Income
-$42M
-483.4% margin
EPS (Diluted)
$-0.75
QoQ Revenue Growth
+105.2%
Cash Flow
Operating Cash Flow
-$34M
Free Cash Flow
-$34M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$382M
Total Liabilities
$118M
Stockholders' Equity
$264M
Cash & Equivalents
$128M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$9M
$2M
+383.8%
Gross Profit
$8M
$2M
+391.0%
Operating Income
-$42M
-$51M
+17.4%
Net Income
-$42M
-$43M
+0.9%
Revenue Segments
Product revenue
$9M
100%
← FY 2022
All Quarters
Q1 2023 →